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Abstract
Background: The natural history of clinical symptoms in the spinocerebellar ataxias (SCA)s has been well
characterised. However there is little longitudinal data comparing cognitive changes in the most common SCA
subtypes over time. The present study provides a preliminary longitudinal characterisation of the clinical and
cognitive profiles in patients with SCA1, SCA2, SCA3, SCA6 and SCA7, with the aim of elucidating the role of the
cerebellum in cognition.
Methods: 13 patients with different SCAs all caused by CAG repeat expansion (SCA1, n = 2; SCA2, n = 2; SCA3,
n = 2; SCA6, n = 4; and SCA7, n = 3) completed a comprehensive battery of cognitive and mood assessments at two
time points, a mean of 7.35 years apart. All patients were evaluated clinically using the Scale for the Rating and
Assessment of Ataxia (SARA) and the Inventory of Non-Ataxia Signs (INAS). Patients underwent structural MRI
imaging at follow-up.
Results: Clinical scale scores increased in all patients over time, most prominently in the SCA1 (SARA) and SCA3
(INAS) groups. New impairments on neuropsychological tests were most commonly observed with executive
functions, speed, attention, visual memory and Theory of Mind. Results suggest possible differences in cognitive
decline in SCA subtypes, with the most rapid cognitive decline observed in the SCA1 patients, and the least in the
SCA6 patients, congruent with observed patterns of motor deterioration. Minimal changes in mood were observed,
and MRI measures of atrophy did not correlate with cognitive decline.
Conclusion: As well as increasing physical impairment, cognitive decline over time appears to be a distinct aspect of the
SCA phenotype, in keeping with the cerebellar cognitive-affective syndrome. Our data suggest a trend of cognitive decline
that is different for each SCA subtype, and for the majority is related to the severity of cerebellar motor impairment.
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Background
The spinocerebellar ataxias (SCAs) are a clinically and
genetically heterogeneous group of dominantly inherited
neurodegenerative disorders, with a prevalence range of
0.9-3 in 100,000 [1]. Over thirty genetic subtypes have
been described; the most common of these are SCA1,
SCA2, SCA3, SCA6 and SCA7 [2]. The SCAs are
associated with a polyglutamine repeat expansion, the
length of which is inversely correlated to the age of on-
set of symptoms [1, 3]. In SCA1, SCA2, SCA3 and
SCA7, symptoms typically develop in the fourth decade,
whereas in SCA6 onset is approximately 20 years later
[4]. Whilst the cardinal clinical features of the SCAs
involve gait and truncal ataxia, dysarthria and limb
ataxia, phenotypic differences include diplopia, progres-
sive visual loss, spasticity, dysphagia, parkinsonism, dys-
tonia, peripheral neuropathy and urge incontinence [5].
The progression of cerebellar symptoms in the SCAs has
been well characterised. A large two-year follow-up study
involving over 400 patients reported the greatest annual
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increase in ataxia severity amongst SCA1 patients,
followed by SCA3 and SCA2 patients [6]. In contrast,
SCA6 patients exhibited a slower, non-linear pattern of
progression. The findings for non-ataxia signs were
similar; the fastest rate of decline was described for
SCA1 while SCA2 and SCA3 were slower but similar.
Some non-ataxia signs were present in SCA6 but no
progression was observed over the two-year period.
Polyglutamine repeat length and age of onset were as-
sociated with the more rapid clinical progression in
SCA1 and SCA2 patients. In SCA3, clinical progression
was affected by disease duration. In a second study
involving a sub-group of the same sample, clinical pro-
gression was assessed in the context of MRI-based
volumetry [7]. This study demonstrated a correlation
between ataxia symptoms and brainstem atrophy in
SCA1 and SCA3. In addition, cerebellar atrophy was
also associated with symptoms in SCA3. A comparison
of clinical progression in SCA7 patients amongst other
SCA groups has yet to be completed, but this phenotype
is known to involve retinal degeneration and progressive
visual loss [1, 8].
Cognitive impairments have been described in many
SCA subtypes and patterns of impairment vary consid-
erably [9–11]. Deficits in attention, executive functions,
visuoconstructive skills, visual and verbal memory and
processing speed have all been reported. Personality
changes and difficulties in identifying social emotions
have also been described [12, 13]. Deficits in executive
function have been consistently reported in SCA1, SCA2,
SCA3 and SCA6 [14–20]. In addition, visual memory,
visual attention and visuo-spatial reasoning impairments
have been described in SCA3 [21, 22]. To the best of our
knowledge, no studies have described the neuropsycho-
logical profile or clinical course of SCA7 patients in
detail. Relatively few studies have described the cogni-
tive changes over time in SCAs. One follow-up study
involving 10 SCA2 patients over an 8.5 year interval
demonstrated a significant decline in non-verbal mem-
ory functions [23]. However verbal memory and execu-
tive functions, which were impaired at baseline, did not
further deteriorate. In another study involving 11 SCA3
patients over a 3.5 year interval, declines in verbal
learning, verbal memory and visual memory were re-
ported [24]. It is also worth noting that amongst the
autosomal dominant cerebellar ataxias, SCA2 is most
commonly associated with dementia [25, 26].
We have previously carried out preliminary cognitive
characterisations of five common SCA groups using an
identical battery of neuropsychological tests, designed to
take into account the specific disabilities associated with
ataxia [27, 28]. The findings of these studies indicated a
relatively similar cognitive profile for SCA1, SCA7 and
SCA6 patients; SCA1 and SCA6 groups had relatively
intact profiles and only selective deficits were noted in
SCA7, primarily affecting executive function. In contrast,
the SCA2 and SCA3 patients showed the greatest cogni-
tive impairments. Attention was impaired in some of the
patients in all groups except the SCA7 group and frontal
executive deficits were present in all but the SCA1
group. Memory impairments were noted in SCA3,
SCA6, and SCA7. These studies also examined social
cognition, using the Theory of Mind test, and found that
SCA3 and SCA6 groups performed poorly, as did one
SCA1 individual. However, SCA2 and SCA7 groups did
not differ significantly in their performance to normal
controls. The aim of the current study is to provide a
longitudinal characterisation of the clinical and cognitive
profiles in SCA1, SCA2, SCA3, SCA6, and SCA7 patients
from the original cohorts using follow-up data.
Methods
Patients
Of the 23 genetically confirmed SCA1, SCA2, SCA3,
SCA6 and SCA7 patients who completed testing at base-
line in our previous studies, 13 were available to be
assessed at follow-up. The sample included two patients
with SCA1, two with SCA2, two with SCA3, four with
SCA6, and three with SCA7. Patients underwent two
sets of clinical and neuropsychological assessment (base-
line, follow-up) at the National Hospital for Neurology
and Neurosurgery, with a mean inter-assessment interval
of 7.5 years (SD 0.92 years). Structural neuroimaging
was performed at follow-up. In addition, allele expansions
were retrieved from the Department of Neurogenetics at
the National Hospital for Neurology and Neurosurgery.
The study was approved by the joint research ethics com-
mittee of the National Hospital for Neurology and Neuro-
surgery and the Institute of Neurology and performed in
accordance with the ethical standards prescribed by the
1964 Declaration of Helsinki. All patients gave informed
consent before participating.
Clinical assessment
Ataxia symptoms and signs were assessed by a neurologist
using SARA. The scale consists of eight items related to
(1) gait, (2) stance, (3) sitting, (4) speech disturbance, (5)
finger chase, (6) nose-finger test, (7) fast alternating hand
movements, and (8) heel-shin slide. Total scores range
from 0 to 40, with a higher score indicating a more severe
phenotype. Non-ataxia signs were assessed by a neurolo-
gist using the INAS. The inventory is a list comprising 30
items which are grouped into 16 non-ataxia signs including
areflexia, hyperreflexia, extensor plantar response, spasti-
city, paresis, amyotrophy, fasciculations, myoclonus, rigid-
ity, chorea, dystonia, resting tremor, sensory symptoms,
brainstem oculomotor signs, urinary dysfunction and
cognitive impairment. The presence of absence of each of
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these signs is attributed a numerical value of either 1 or 0,
respectively, providing a total score out of 16. In addition,
we extracted and reported scores for impaired visual acuity
(item 25).
Neuropsychological assessment
A battery of neuropsychological and social cognitive
tests was administered to all patients. The cognitive
battery assessed the following domains: current intel-
lectual functioning, premorbid intellectual functioning,
verbal and visual recognition memory, nominal func-
tions, calculation perceptual functions and attention
and executive functions. The specific tests used have been
detailed in our previous studies [27, 28]. Similarly, impair-
ments in tests were classified as before to maintain
consistency. Tests were chosen which had minimal
demands on upper limb functions to reduce the influence
of ataxia symptoms. Social cognition was tested using the
Theory of Mind Test devised by Blair & Cipolotti and
adapted by Van Harskamp et al. [29, 30]. A description of
this test can be found in our previous studies [27, 28].
Mood was assessed using the Patient Health Question-
naire (PHQ-9) which is a brief, reliable and valid measure
of depression severity [31]. PHQ-9 scores greater or equal
to 10 indicate depression and scores of 5, 10, 15, and 20
represent mild, moderate, moderately severe, and severe
depression, respectively [32].
Neuroimaging
Structural MRI data (1.5 and 3 T) were acquired at
follow-up using T1-weighted, T2-weighted and FLAIR
acquisitions. These data were analysed and scored accord-
ing to severity of atrophy in the cerebellum, brainstem,
cortical and subcortical regions by a neuroradiologist. No
focal vascular, space-occupying or inflammatory lesions
were identified in our dataset.
Data
For clinical assessments, baseline scores and change in
score over time will be presented as group averages for
both the SARA and INAS. Neuropsychological assess-
ments will be reported in terms of the number of patients
that achieve a score below standardised thresholds, sug-
gesting impairment. Specific assessment thresholds are
displayed in Table 3. Together with MRI atrophy scores,
clinical, neuropsychological and mood scores will be
described in terms of basic trends across groups. Statis-
tical correlations will not be calculated due to the limited
sample size.
Results
Sample demographics
Demographic details including age at onset, age at base-
line, disease duration and CAG repeat length are displayed
for each group in Table 1. The SCA1 group were notably
younger, and the SCA6 group notably older, than the
remaining groups at baseline. Disease duration was lowest
in the SCA1 group. The CAG repeat lengths were clus-
tered within SCA groups. With the exception of one, all
patients had an estimated premorbid level of functioning
in the average or high-average range. Of note, one SCA3
patient was not assessed on several verbal tests due to
English being a second language. Notable changes in
comorbidity include one SCA6 patient and one SCA7
patient being diagnosed with depression between baseline
and follow-up. No other psychiatric or neurological diag-
noses had been made during the interval.
Clinical assessments
Baseline and follow-up scores for SARA and INAS are
displayed in Table 2. Figure 1 shows longitudinal change
in SARA score over time or each patient. All patients
exhibited an increase in SARA score over time, repre-
senting longitudinal decline. Group average changes in
SARA score ranged from 4.25 to 9.5. Patients in the
SCA3 group were most impaired at baseline, whilst
those in the SCA2 group were least impaired. The greatest
increase in SARA score was observed in the SCA1 group.
The remaining groups showed comparable decline over
time, with patients in the SCA6 group showing the smal-
lest change in score. The INAS scores increased in all
groups over time. Group average changes in INAS score
ranged from 0.5 to 4.5. Patients in the SCA1 group were
most impaired at baseline, whilst those in the SCA6 group
were least impaired. The greatest increase in INAS score
was observed in the SCA3 group. The SCA2 and SCA6
groups showed minimal change in INAS score over time.
Of note, INAS scores detected impaired visual acuity in all
SCA7 patients, both at baseline and follow-up.
Neuropsychological assessment
In general, calculation functions, nominal functions and
perceptual functions were preserved in all groups both
at baseline and follow-up. Performance IQ deficits were
noted in each group except the SCA3 group, whilst
verbal IQ deficits were only observed in the SCA1 and
SCA6 groups.
Table 3 shows executive function, speed, attention
and recognition memory data at baseline and follow-
up, reported as number of patients within each group
that were rated as impaired according to standardised
threshold scores. The SCA1 group was the only group
to exhibit decline in both verbal and visual recognition
memory over time. The SCA6 group demonstrated no
deficit in recognition memory, either at baseline or
follow-up. Tests of speed, attention and executive func-
tion revealed deficits in all groups, albeit to varying de-
grees. Table 4 shows the scores for each patient on the
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Theory of Mind comprehension task. The SCA1, SCA2
and SCA7 groups were just above the threshold of im-
pairment at baseline, whereas at follow-up, all groups
had scored below threshold, again to varying degrees.
The SCA7 group demonstrated the smallest decrease in
score over time. In light of comprehension impair-
ments, further comparison of the mental and physical
justifications was not deemed appropriate (Additional
file 1).
Neuroimaging
MRI data are displayed in Fig. 2. Imaging was available for
12 of 13 patients at follow-up (one SCA6 patient did not
complete an MRI visit). Cerebellar atrophy was ubiqui-
tous, with all but two SCA3 patients exhibiting moderate
or severe atrophy. Brainstem atrophy was observed in 11
of 12 patients, and this was moderate or severe in all but
two cases. The SCA1 and SCA2 patients exhibited the
greatest degree of cerebellar and brainstem atrophy. Cere-
bellar atrophy without brainstem atrophy was reported in
one SCA6 patient. Subtle linear sagittal hyperintensities in
the midline of the pons were reported in nine patients,
involving all SCA groups. Mild frontal cortex atrophy was
observed in six patients, involving all SCA groups. Mild
parietal cortex atrophy was reported in one SCA2 patient.
There was no occipital or temporal cortex atrophy noted
within our sample. Mild subcortical atrophy was observed
in all SCA7 patients.
Mood
The PHQ-9 scores indicated that no patients met criteria
for severe depression at baseline or follow-up. However,
one SCA6 patient met criteria for major depression at
baseline and follow-up but with little change over time. Of
the remaining patients, one SCA1 and one SCA3 patient
had a mild level of depression at baseline. At follow-up,
the SCA3 patient continued to have mild depression while
the SCA1 patient improved and no longer met this criter-
ion. All other patients tested were below the cut-off for
depression.
Discussion
This study provides a preliminary characterisation of
longitudinal change in both clinical and cognitive pro-
files in a small group of patients with SCA1, SCA2,
SCA3, SCA6 and SCA7. To our knowledge, there has
yet to be a follow-up study that incorporates both clin-
ical and neuropsychological progression in these SCA
patients, involving a follow-up period of this size. We
used an identical battery of assessments to those used in
previous studies, which has allowed for a reliable com-
parison of performance at both points in time [27, 28].
The SARA scores demonstrated progressive decline in
ataxia symptoms in all patients. Despite having the
shorter disease duration and shorter follow-up period,
the SCA1 group exhibited the greatest increase in SARA
over time, consistent with more rapid deterioration
noted in this group of patients [6]. Whilst baseline INAS
scores were highest in SCA1, the decline over time was
not the greatest seen in our sample, as might be expected.
Nevertheless, a pattern of decline involving both cerebellar
and non-cerebellar domains was observed, consistent with
the moderate to severe cerebellar and brainstem atrophy
observed in this group [7]. The baseline SARA scores in
the SCA3 patients were notably greater than the other
Table 1 Sample Characteristics
CAG repeat length (range)
Group n Age at onset (range) Age at baseline (range) Follow-up period Normal allele Expanded allele
SCA1 2 30.5y (30–31) 36y (36) 6.5y 30.5 (29–32) 50.5 (50–51)
SCA2 2 40.5y (37–44) 52.5y (50–55) 7y 21.5 (21–22) 41 (41)
SCA3 2 32.5y (25–40) 45y (37–50) 8y 16 (14–20) 72.3 (70–74)
SCA6 4 47.5y (28–59) 42.5y (41–65) 7y 12.3 (11–13) 22.5 (22–23)
SCA7 3 33.7y (29–38) 42.3y (38–50) 7y 13.7 (12–15) 56.3 (46–65)
All values represent the group average (mean). Range values are given in brackets
Table 2 SARA and INAS scores for each patient at baseline and
follow-up
SARA INAS
Patient Baseline Follow-up Change Baseline Follow-up Change
SCA1 10 15.5 +5.5 5 6 +1
SCA1 10.5 24 +13.5 3 5 +2
SCA2 10 14.5 +4.5 5 5 0
SCA2 9 14.5 +5.5 2 3 +1
SCA3 23.5 28 +4.5 3 6 +3
SCA3 17.0 2153 +7.5 3 9 +6
SCA6 14.5 20.5 +6 1 1 0
SCA6 11.5 16 +4.5 1 1 +2
SCA6 10.5 13 +2.5 0 2 +2
SCA6 16 20 +4 0 1 +1
SCA7 18 26 +8 3 5 +2
SCA7 13 17.5 +4.5 3 5 +2
SCA7 9.5 15 +5.5 2 3 +1
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groups, which might be in part attributable to the rela-
tively early onset of disease and to the greater CAG ex-
pansion lengths observed in this group. In addition, the
SCA3 group demonstrated the greatest increase in INAS
score over time, reflecting the high frequency of non-
ataxia features described in this subtype [6, 33]. The SCA2
group displayed the least decline in SARA and INAS
scores over time when compared to the SCA1 and SCA3
groups. This pattern of SCA2 as the least severe pheno-
type amongst the type I autosomal dominant cerebellar
ataxias is consistent with previous evidence [6, 26]. Inter-
estingly, cerebellar and brainstem atrophy were rated as
severe in both SCA2 patients. This is in line with previous
quantitative imaging evidence that indicates a lack of cor-
relation between infratentorial volume loss and neuro-
logical deficit in SCA2 [34]. The SCA6 patients exhibited
the least decline on SARA and only mild decline on INAS,
consistent with the slower and non-linear decline de-
scribed in this sub-type [6]. Although the relatively low
INAS scores in this group might support the traditional
notion of SCA6 being a “pure cerebellar ataxia”, MRI find-
ings demonstrated brainstem atrophy in two of three pa-
tients and frontal cortex atrophy in two of three patients.
It should be noted that, consistent with the later onset re-
ported in SCA6, the patients in this group were older than
the majority of other patients in our sample. It is thus
Fig. 1 SARA scores over time for each patient
Table 3 Impairment on neuropsychological assessments in each group
SCA 1 (n = 2) SCA2 (n = 2) SCA3 (n = 2) SCA6 (n = 4) SCA7 (n = 3)
Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up
Executive Function
Verbal Fluency FAS (<10th%ile) 0 1 0 0 1 2 0 0 1 1
Hayling Test (scaled score <3) 0 0 1 1 1 1 2 2 2 1
Stroop C-W Test (<5th%ile) 0 2 0 1 1 1 0 1 2a 1a
Speed and Attention
Oral Symbol Digit Modalities Test
(<5th%ile)
0 2 1 1 1 2 1a 1a 2 2
Elevator Counting with Distraction
(<5th%ile)
1 1 1 1 1 0 0 0 0 0
Elevator Counting (score <5) 0 0 0 0 0 1 0 0 0 0
Recognition Memory
RMW (<5th%ile) 0 1 0 1 0 0 0 0 0 0
RMF (<5th%ile) 0 2 0 0 1 2 0 0 1 2
Values displayed are number of patients that were impaired on each task, with specific thresholds in brackets (based on normalised scores). RMW/RMF = Recognition
Memory Test, Words/Faces. ameans some data missing
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important to include the possibility of the effects of ageing
when trying to account for this pattern of performance
and atrophy. The SCA7 group demonstrated moderate
decline on SARA and INAS scores over time, despite a
shorter disease duration than most. Expanded allele CAG
repeat lengths in this group were greater than in the
SCA1, SCA2 and SCA6 groups, offering some explanation
for the younger age at onset and the more marked clinical
progression in these patients [35]. It is also important to
note the presence of visual acuity impairments in all of
the SCA7 patients at baseline, consistent with the typical
phenotype in this subgroup. Mild subcortical atrophy was
observed in all SCA7 patients, which could be associated
with the cerebro-cerebellar atrophy known to correlate
with ataxia severity in these patients [36].
The SCA1 patients exhibited the greatest degree of im-
pairment over time on neuropsychological testing, con-
gruent with the motor deterioration seen in this subtype.
In particular executive function, speed and attention dete-
riorated from normal scores at baseline. This pattern of
decline raises the question as to whether there exists a
common patho-anatomical basis to the motor and cogni-
tive manifestations of SCA1. Volumetric analyses have
noted a correlation between brainstem atrophy and motor
symptoms in SCA1, and so it would be interesting to
investigate whether infratentorial volume has any direct im-
pact on cognitive performance in these patients [7, 12, 37].
The decline in visual memory in the SCA1 patients is not
consistent with another longitudinal study, however the
follow-up period in the present study was significantly
greater [14]. Although there is little evidence describing the
cognitive profile of murine models of the SCAs, it is worth
noting that severe deficits in visuospatial functions, as
assessed using the spatial version of the Morris water
maze, have been reported in transgenic SCA1 mice [38].
Furthermore, these deficits were associated with dimin-
ished paired-pulse facilitation in hippocampal CA1 neu-
rons, implicating medial temporal lobe pathology in the
cognitive profile of these mouse models. Decline in visual
memory was also observed in SCA3 patients, which is
consistent with previous reports of poor performance on
tasks of visual memory, visual attention and visuospatial
functions [21, 22]. Interestingly, a transgenic SCA3 mouse
model exhibited normal performance on the Morris water
maze, perhaps highlighting the often challenging transla-
tion of such measures between murine models and
patients [39]. In the tasks of executive function, speed and
attention, the SCA3 patients also exhibited decline al-
though deficits were already more pronounced at baseline.
Whereas the pattern of cognitive decline seen in the
SCA1 and SCA3 groups was loosely comparable, their
clinical scores were quite different: the SCA1 patients
showed a lower SARA score but a higher INAS score
compared to the SCA3 group, and it was the latter group
that exhibited the more pronounced change on the INAS
over time. When considered in the context of the more
severe atrophy noted in the SCA1 group, these results
might suggest that the cognitive decline observed in
these patients is not entirely attributable to the infra-
tentorial changes seen on MRI. The SCA2 group dis-
played the more stable neuropsychological profile over
Table 4 Theory of mind comprehension scores for each patient
Patient Baseline score Follow-up score Change over time
SCA1 14 9a −5
SCA1 14 13a −1
SCA2 13a 13a 0
SCA2 14 14 0
SCA3 14 12a −2
SCA3 12a 12a 0
SCA6 14 14 0
SCA6 12a 6a −6
SCA6 14 13a −1
SCA6 12a 11a −1
SCA7 14 14 0
SCA7 14 13a −1
SCA7 14 14 0
aindicates scores that are ≥2 standard deviations below healthy control group cores
Atrophy scores: 1= mild, 2= moderate, 3= severe
Fig. 2 Regional atrophy on MRI brain in each SCA patient
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time, which is consistent with another longitudinal study
involving a similar follow-up period [22]. Although im-
pairments were noted in this group on tasks of speed, at-
tention and executive function, relatively little change
over time was observed. Ataxin-2 knockout mice dis-
played normal visuospatial functions and associated intact
hippocampal long-term potentiation, providing some sug-
gestion of unaffected memory functions in these models
[40]. In the motor domain, the SCA2 patients exhibited
mild decline in SARA and INAS scores, suggesting a gen-
erally less severe phenotype. The severe cerebellar and
brainstem atrophy in this group is consistent with the
suggestion that early disruption to cerebro-cerebellar
pathways yields a non-progressive “frontal-executive dys-
function” syndrome in SCA2 [16, 23]. The SCA6 patients
were less impaired overall compared to the other
groups, in line with the milder progression of motor
symptoms observed in this group. Some decline was
noted, specifically in executive functioning, speed, atten-
tion and performance IQ, where the latter has not previ-
ously been demonstrated [20, 41]. The presence of mild
frontal cortex atrophy in two of these patients may also
have contributed to these deficits, which in turn must be
considered in the context of age; the SCA6 patients were
among the oldest in our sample and so potential age-
related changes in cortical structure should not be over-
looked [42]. The SCA7 patients demonstrated decline on
the tests of speed, attention and executive function, and
this group were notably more impaired at baseline. Im-
portantly, we used aural assessments in all domains thus
controlling for any visual deficits in this group. The SCA7
patients were impaired on both verbal and visual measures
of executive function. Interestingly, only the visual tests of
speed and attention yielded abnormal scores, whilst the
verbal tests revealed no or little impairment. It is therefore
possible that speed and attention are not necessarily af-
fected in SCA7, as revealed by tests that don’t rely on vis-
ual input. This group did exhibit decline on tasks
involving visual memory, performance IQ and visual-
perceptual functions, as would be expected [43, 44]. Mild
subcortical atrophy was noted in each SCA7 patient, how-
ever the relevance of this to the cognitive profile described
is difficult to ascertain. Theory of Mind comprehension
scores revealed deficits in most patients at follow-up, and
no obvious group differences were detected. Impair-
ments in social cognition thus appear to be an import-
ant component of the SCA profile, which might not be
associated with clinical or other neuropsychological
measures [45].
In the current study, no correlations between clinical de-
cline and mood scores were observed. Furthermore, cogni-
tive decline and mood scores were not related. Indeed, a
number of patients exhibited improvements in depression
ratings whilst deteriorating on neuropsychological testing.
Two patients were taking antidepressants during the study
follow-up period and despite medication, PHQ-9 scores
remained static. It is thus felt that medications had an in-
significant effect on mood scores in our study. In light of
the sample size it is difficult to extrapolate these results,
but a similar lack of association between mood, clinical
and cognitive scores has been noted previously in SCA
patients [46].
The numbers of patients within each SCA subtype
group were small, making comparisons difficult. Our
findings are therefore very preliminary and only larger
studies will be able to confirm our findings. However,
despite the sample size of our cohort, many of our find-
ings seem to fit with previous research suggesting dif-
ferent patterns of cognitive decline according to SCA
subtype. We believe that this is due in part to the
viability of our neuropsychological battery designed
specifically for ataxia patients. The use of the SARA
and INAS for physical symptoms is also consistent with
previous research in a large cohort of patients [47]. MR
imaging was only performed at follow-up, and so we
have been unable to comment on progressive change in
brain structure in these patients. Indeed, longitudinal
imaging data should be used in future studies in order
to help clarify any anatomical correlates of cognitive
function in the SCAs. Our use of the PHQ-9 may have
also limited our findings on mood as this does not
extensively examine both anxiety and depression.
Conclusion
Cognitive decline seems to be a distinct aspect of the
SCA phenotype, independent of mood disturbance.
Specifically, tests of executive function, speed and
attention were most sensitive to change over time in
the majority of our sample. We have identified a trend
between cognitive and clinical decline in specific SCA
subtypes. The SCA1 and SCA3 patients exhibited the
more severe cerebellar impairments (SARA) together
with the greatest cognitive decline over time. In con-
trast, the SCA2 and SCA6 groups demonstrated the
least decline on both cerebellar and cognitive assess-
ments. This pattern of motor impairment amongst SCA
subtypes has recently been confirmed in a large obser-
vational study [47]. Cognitive performance does not
seem to be associated with the cerebellar impairments
observed in SCA7. Furthermore, the cognitive profile
seems independent of the extra-cerebellar manifesta-
tions of disease in all studied patients as measured by
the INAS. We were unable to identify MRI indices of
atrophy that might explain the different patterns of cogni-
tive impairment detected in SCA subtypes. The cognitive
profiles we report here adhere to the previously
described “Cerebellar Cognitive-Affective Syndrome”
originally described in patients with focal cerebellar
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lesions [12]. Studies involving large samples and longitu-
dinal imaging protocols will help to elucidate further the
patho-anatomical basis of different neuropsychological
impairments in different SCA subtypes, and in so doing
contribute to our understanding of the role of the cerebel-
lum in cognition.
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